Neuroinflammation Focus Target neurological therapeutic opportunities by leveraging Renew Biopharma's proprietary enzymatic chemistry platform to develop brain-penetrant molecules that modulate inflammation pathways, addressing high-need indications such as Traumatic Brain Injury (TBI) where FDA-approved treatments are lacking.

CNS Penetrant Pipeline Position the company as a specialist in blood-brain barrier crossing compounds that engage brain receptors to reduce neuroinflammation, creating a differentiator for partnerships with pharma firms seeking CNS-focused anti-inflammatory assets.

Strategic IP Advantage Leverage a robust IP portfolio around engineered enzymes and prenylation-based synthesis of alkylresorcinol derivatives to pursue collaborations, licensing, or co-development deals centered on platform-enabled therapeutic derivatives.

Early Stage Expansion Identify opportunities to collaborate with larger biotechs on early-stage discovery and preclinical programs, particularly in neurology and neurotrauma, leveraging Renew’s compact team to accelerate partner-driven research milestones.

Evidence-ready Narratives Craft sales narratives around scalable, efficient enzymatic processes that offer capital-efficient drug development compared to traditional medicinal chemistry, highlighting potential speed-to-clinic advantages for potential licensees or co-development partners.